Zydus Lifesciences Ltd Share Price & Stock Analysis

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) is an Ahmedabad, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,19,651 Cr, it ranks #92 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,189.90 (as of 16 Nov 2026), the share price is 6.1% below its 52-week high of ₹1,266.60 and 42.4% above its 52-week low of ₹835.50. The share price is up 26.0% over one year and up 1.9% over three months.

Key Metrics

Current Price₹1,189.90
Market Cap₹1,19,651 Cr
NSE SymbolZYDUSLIFE
BSE Code532321
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio24.1
Return on Equity18.32%
Return on Assets8.13%
52-Week Range₹835.50 – ₹1,266.60
1-Year Price Change+26.0%
3-Month Price Change+1.9%
Beta (1Y)0.26
Dividend Yield0.08%
HeadquartersAhmedabad, Gujarat
Websitezyduslife.com

Latest Quarterly Results — Q2 FY27

Revenue₹7,910 Cr
Net Profit₹928 Cr
Net Margin11.7%
EPS (Basic)₹9.28
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Zydus Lifesciences Ltd Quarterly Revenue and Profit Trend

Zydus Lifesciences Ltd reported revenue of ₹7,910 Cr in Q2 FY27, up 29.2% from ₹6,123 Cr in Q2 FY26 and down 1.3% from ₹8,017 Cr in Q1 FY27. It posted a net profit of ₹928 Cr for the quarter, against a net profit of ₹1,239 Cr in Q2 FY26 (down 25.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹6,123 Cr (Q2 FY26) to ₹8,017 Cr (Q1 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹7,910 Cr₹928 Cr11.7%
Q1 FY27₹8,017 Cr₹990 Cr12.4%
Q4 FY26₹7,587 Cr₹1,341 Cr17.7%
Q3 FY26₹6,865 Cr₹1,023 Cr14.9%
Q2 FY26₹6,123 Cr₹1,239 Cr20.2%
Q1 FY26₹6,574 Cr₹1,521 Cr23.1%
Q4 FY25₹6,528 Cr₹1,244 Cr19.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 75.01% of Zydus Lifesciences Ltd's shares as of Sept 2026, against 74.99% in Sept 2025 (+0.02 percentage points). Delivery averaged 49.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopa

Products and Services

1. Pharmaceuticals-This segment engages in the research, development, production, marketing, and distribution of active pharmaceutical ingredients and human formulations. 2. Consumer Products-This segment engages in the development, production, marketing, and distribution of health and wellness products. 3. Segment Adjustment-0

Business Segments

1. Pharmaceuticals (excl. Medical Technologies)-82.6% 2. Consumer Products-14.6% 3. Medical Technologies-2.9%

Zydus Lifesciences Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Glenmark Pharmaceuticals Limited₹75,556 Cr55.114.07%₹4,157 Cr+45.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd is trading at ₹1,189.90, with a market capitalisation of ₹1,19,651 Cr.

Which sector does Zydus Lifesciences Ltd belong to?

Zydus Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd has a P/E of 24.1 and a return on equity of 18.32%.

What is the stock symbol of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd is listed on the NSE under the symbol ZYDUSLIFE and on the BSE under the scrip code 532321.

How has Zydus Lifesciences Ltd's share price moved over the past year?

Zydus Lifesciences Ltd's share price is up 26.0% over one year and up 1.9% over three months. Its 52-week range is ₹835.50 to ₹1,266.60.

What were Zydus Lifesciences Ltd's latest quarterly results?

In Q2 FY27, Zydus Lifesciences Ltd reported revenue of ₹7,910 Cr and net profit of ₹928 Cr, with basic EPS of ₹9.28 (consolidated, parsed from the company's exchange filing).

How have Zydus Lifesciences Ltd's revenue and profit changed over the past year?

Zydus Lifesciences Ltd reported revenue of ₹7,910 Cr in Q2 FY27, up 29.2% from ₹6,123 Cr in Q2 FY26 and down 1.3% from ₹8,017 Cr in Q1 FY27.

What is the promoter holding in Zydus Lifesciences Ltd?

Promoters held 75.01% of Zydus Lifesciences Ltd's shares as of Sept 2026, against 74.99% in Sept 2025 (+0.02 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.